191 related articles for article (PubMed ID: 25189308)
1. Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre.
Karim F; Shaikh U; Adil SN; Khurshid M
Singapore Med J; 2014 Aug; 55(8):443-7. PubMed ID: 25189308
[TBL] [Abstract][Full Text] [Related]
2. PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.
Tang FF; Lu SY; Zhao XS; Qin YZ; Liu XH; Jia JS; Wang J; Gong LZ; Jiang Q; Zhao T; Shi HX; Chang YJ; Huang XJ; Jiang H
Br J Haematol; 2021 Dec; 195(5):722-730. PubMed ID: 34405393
[TBL] [Abstract][Full Text] [Related]
3. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
4. Treatment Outcomes Of Patients With Newly Diagnosed Acute Promyelocytic Leukemia; Experience From A Developing Country.
Javed H; Chudary QU; Iftikhar R; Shahbaz N; Ali M; Hamayun S
J Ayub Med Coll Abbottabad; 2022; 34(4):791-796. PubMed ID: 36566401
[TBL] [Abstract][Full Text] [Related]
5. Early treatment of acute promyelocytic leukaemia is accurately guided by the PML protein localisation pattern: real-life experience from a tertiary New Zealand centre.
Chien N; Petrasich M; Chan G; Theakston E; Ruskova A; Eaddy N; Hawkins T; Berkahn L; Doocey R; Browett PJ; Green TN; Kalev-Zylinska ML
Pathology; 2019 Jun; 51(4):412-420. PubMed ID: 30876657
[TBL] [Abstract][Full Text] [Related]
6. Improved outcome in early induction deaths in patients with acute promyelocytic leukemia after therapeutic and supportive interventions: a follow up study of seven-years' experience at a tertiary care center.
Shaikh MU; Ali N; Karim F; Raheem A; Sarwar S
Am J Blood Res; 2020; 10(4):82-89. PubMed ID: 32923087
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic results with apl 93 protocol in acute promyelocytic leukemia (34 cases)].
Jeddi R; Hdiji S; Kacem K; Ben Lakhal R; Aissaoui L; Ben Abid H; Belhadj Ali Z; Meddeb B
Tunis Med; 2006 Nov; 84(11):717-20. PubMed ID: 17294898
[TBL] [Abstract][Full Text] [Related]
8. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study.
Avvisati G; Lo Coco F; Diverio D; Falda M; Ferrara F; Lazzarino M; Russo D; Petti MC; Mandelli F
Blood; 1996 Aug; 88(4):1390-8. PubMed ID: 8695858
[TBL] [Abstract][Full Text] [Related]
9. Expression of PML-RARα is up-regulated during ATRA and arsenics combined induction without influence on long-term prognosis of acute promyelocytic leukemia.
Zhu HH; Qin YZ; Lai YY; Shi HX; Liu YR; Jiang B; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):872-8. PubMed ID: 23998577
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial.
Kutny MA; Alonzo TA; Abla O; Rajpurkar M; Gerbing RB; Wang YC; Hirsch BA; Raimondi S; Kahwash S; Hardy KK; Hardy S; Meshinchi S; Gamis AS; Kolb EA; Feusner JH; Gregory J
JAMA Oncol; 2022 Jan; 8(1):79-87. PubMed ID: 34762093
[TBL] [Abstract][Full Text] [Related]
11. No prognostic significance of normalized copy number of PML-RARA transcript at diagnosis in patients with acute promyelocytic leukemia.
Rasekh EO; Elsayed GM; Fathy S
Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):119-125. PubMed ID: 32735792
[TBL] [Abstract][Full Text] [Related]
12. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021.
Gill H; Raghupathy R; Lee CYY; Yung Y; Chu HT; Ni MY; Xiao X; Flores FP; Yim R; Lee P; Chin L; Li VWK; Au L; Au WY; Ma ESK; Mohan D; Kumana CR; Kwong YL
BMC Cancer; 2023 Feb; 23(1):141. PubMed ID: 36765318
[TBL] [Abstract][Full Text] [Related]
13. [Progress in biology and the treatment of acute promyelocytic leukemia].
Robak T
Acta Haematol Pol; 1993; 24(1):13-21. PubMed ID: 8488732
[TBL] [Abstract][Full Text] [Related]
14. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
Sanz MA; Montesinos P; Kim HT; Ruiz-Argüelles GJ; Undurraga MS; Uriarte MR; Martínez L; Jacomo RH; Gutiérrez-Aguirre H; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Vellenga E; Holowiecka A; González-Huerta AJ; Fernández P; De la Serna J; Brunet S; De Lisa E; González-Campos J; Ribera JM; Krsnik I; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Rego EM;
Ann Hematol; 2015 Aug; 94(8):1347-56. PubMed ID: 25975975
[TBL] [Abstract][Full Text] [Related]
15. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia.
Reiter A; Lengfelder E; Grimwade D
Acta Haematol; 2004; 112(1-2):55-67. PubMed ID: 15179005
[TBL] [Abstract][Full Text] [Related]
17. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
18. ABO identical and washed blood transfusions as candidate strategies to reduce early mortality in acute promyelocytic leukemia.
Sahai T; Henrichs K; Refaai M; Heal JM; Kirkley SA; Schmidt AE; Mendler JH; Masel D; Liesveld J; Aquina C; Blumberg N
Leuk Res; 2017 Nov; 62():1-3. PubMed ID: 28963906
[TBL] [Abstract][Full Text] [Related]
19. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
[TBL] [Abstract][Full Text] [Related]
20. The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia.
Zhao J; Liang JW; Xue HL; Shen SH; Chen J; Tang YJ; Yu LS; Liang HH; Gu LJ; Tang JY; Li BS
Leukemia; 2019 Jun; 33(6):1387-1399. PubMed ID: 30575821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
